Ansh labs launches two new immunoassays for SARS-COV2

Ansh labs has launched two new immunoassays, SARS-CoV2 IgG and IgM ELISAs, to assist in the fight against the Covid-19 pandemic.
Ansh Labs is releasing these two kits for sale in the United States under the provisions outlined in Section D of Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency. At the time of going to press, these tests were under review by the FDA for an Emergency Use Authorization.
IgM antibody is the first to be produced in response to viral proteins (antigens) and will be primarily detectable during the early onset of the disease. IgG antibodies are long-lasting and can persist in the bloodstream for many years after infection. This test has the advantage of detecting not only individuals with active infection (IgM), but also those who were previously exposed to the virus and may have subsequently developed immunity (IgG).
Testing for SARS-CoV2 antibodies can help in epidemiological surveillance about the spread of the virus and possible herd immunity. Ansh Labs’ SARS-CoV2 ELISAs are highly accurate with IgG ELISA offering 96% specificity and IgM ELISA offering 99% specificity.
For more information, visit:
Supplier: [No title]

Mail the supplier